Back to search

Netherlands· NL-0a4acb1319f9

PROVARIVAX, poeder en oplosmiddel voor suspensie voor injectie in een voorgevulde spuit

A varicella, live attenuated product containing levend verzwakt varicellavirusvaccin, stam oka geproduceerd in humaan diploïde cellijn mrc5, registered in Netherlands by Medcor Pharmaceuticals B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC J07BK01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedPROVARIVAX, poeder en oplosmiddel voo…ATCJ07BK01REGISTER NO.NL-0a4acb1319f9PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Varicella, live attenuated is registered in 11 of 19 countries.

Countries holding a registration under ATC J07BK01 (varicella, live attenuated), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Varicella, live attenuated · ATC J07BK01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LEVEND VERZWAKT VARICELLAVIRUSVACCIN, stam OKA geproduceerd in Humaan diploïde cellijn MRC5
Manufacturer
Medcor Pharmaceuticals B.V.
Country
Netherlands (NL)
ATC code
J07BK01
ATC class
Varicella, live attenuated
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    133200//29215

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2db89ce9-d4d3-463f-b6a7-c834a56ed85f
GET /v1/drugs/2db89ce9-d4d3-463f-b6a7-c834a56ed85f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder en oplosmiddel voor suspensie voor injectie",
  "route": "Subcutaan gebruik, Intramusculair gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h29215_smpc.pdf",
  "strength": null,
  "atc_label": "Varicella, Live Attenuated",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg133200",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "GELATINE, GEHYDROLYSEERD, AFKOMSTIG VAN VARKEN",
    "KALIUMCHLORIDE (E 508)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "NATRIUMCHLORIDE",
    "NATRIUMGLUTAMAAT 1-WATER (E 621)",
    "SACCHAROSE",
    "UREUM (E 927B)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "LEVEND VERZWAKT VARICELLAVIRUSVACCIN, stam OKA geproduceerd in Humaan diploïde cellijn MRC5"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h133200.pdf",
  "authorised_at": "2024/12/12",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "133200//29215",
  "additional_monitoring": "N"
}

See everything about varicella, live attenuated.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.